Adimmune Corporation (TPE:4142)
Taiwan · Delayed Price · Currency is TWD 17.55
-0.15 (-0.85%)
Sep 8, 2026, 1:30 PM CST
Adimmune Revenue
Adimmune had revenue of 66.76M TWD in the quarter ending June 30, 2026, a decrease of -38.54%. This brings the company's revenue in the last twelve months to 1.37B, down -15.13% year-over-year. In the year 2025, Adimmune had annual revenue of 1.40B, down -9.99%.
Revenue (ttm)
1.37B
Revenue Growth
-15.13%
P/S Ratio
5.40
Revenue / Employee
2.43M
Employees
564
Market Cap
7.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | -155.49M | -9.99% |
| Dec 31, 2024 | 1.56B | -228.11M | -12.78% |
| Dec 31, 2023 | 1.79B | -466.53M | -20.72% |
| Dec 31, 2022 | 2.25B | 457.85M | 25.52% |
| Dec 31, 2021 | 1.79B | -75.37M | -4.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| Tanvex BioPharma | 657.56M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| Polaris Group | 67.95M |
| Locus Cell | 19.40M |
| AnnJi Pharmaceutical | 959.00K |